Mirum Pharmaceuticals, Inc.MIRM
What Mirum Pharmaceuticals, Inc. does.
We have three approved medicines: LIVMARLI® (maralixibat) (“Livmarli”), CHOLBAM® (cholic acid) capsules (“Cholbam”), and CTEXLI® (chenodiol) tablets (“Ctexli”).
Livmarli is a novel, orally administered, minimally-absorbed ileal bile acid transporter (“IBAT”) inhibitor (“IBATi”) that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (“ALGS”) in the United States (“U.S.”), the European Union (“EU”) and various other countries around the world and for cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (“PFIC”) in the U.S., Canada and Japan and for the treatment of PFIC in the EU. We market and commercialize Livmarli in the U.S., Canada and certain countries in Europe through our specialized and focused commercial team. We have also entered into license and distribution agreements with several rare disease companies for the commercialization of Livmarli in additional countries. We are also seeking to add to the approved indications for Livmarli by conducting the EXPAND study in settings of cholestatic pruritus due to other rare conditions.
In August 2023, we completed the acquisition of assets of Travere Therapeutics, Inc. (“Travere”) that are primarily related to the development, manufacture (including synthesis, formulation, finishing or packaging) and commercialization of chenodiol and Cholbam (also known as Kolbam) (and together with chenodiol, the “Bile Acid Medicines”) pursuant to an asset purchase agreement dated July 16, 2023 (such acquisition, the “Bile Acid Portfolio Acquisition”).
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $19.1M | $77.1M | $186.4M | $336.9M | $521.3M |
| Net income | -$103.3M | -$84.0M | -$135.7M | -$163.4M | -$87.9M | -$23.4M |
| Free cash flow | -$89.3M | -$132.8M | -$120.4M | -$71.1M | $9.3M | $54.9M |
More on MIRM.
- Mirum Pharmaceuticals, Inc. summary
- Mirum Pharmaceuticals, Inc. financial statements
- Mirum Pharmaceuticals, Inc. key metrics
- Mirum Pharmaceuticals, Inc. health scores and style box
- Mirum Pharmaceuticals, Inc. earnings
- Mirum Pharmaceuticals, Inc. dividends
- Mirum Pharmaceuticals, Inc. valuation
- Mirum Pharmaceuticals, Inc. ownership and insiders
- Mirum Pharmaceuticals, Inc. peers
Figures from Mirum Pharmaceuticals, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.